111 related articles for article (PubMed ID: 9484828)
1. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer.
Stattin P; Westin P; Damber JE; Bergh A
Br J Cancer; 1998 Feb; 77(4):670-5. PubMed ID: 9484828
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
3. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.
Westin P; Stattin P; Damber JE; Bergh A
Am J Pathol; 1995 Jun; 146(6):1368-75. PubMed ID: 7778676
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation.
Matsuura H; Hayashi N; Kawamura J; Shiraishi T; Yatani R
Eur Urol; 2000 Feb; 37(2):212-7. PubMed ID: 10705201
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
8. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
9. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
10. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Colecchia M; Frigo B; Del Boca C; Guardamagna A; Zucchi A; Colloi D; Leopardi O
J Clin Pathol; 1997 May; 50(5):384-8. PubMed ID: 9215120
[TBL] [Abstract][Full Text] [Related]
11. Proliferative activity and apoptosis in thymic epithelial neoplasms.
Hiroshima K; Iyoda A; Toyozaki T; Supriatna Y; Shibuya K; Shimamura F; Haga Y; Yoshida S; Fujisawa T; Ohwada H
Mod Pathol; 2002 Dec; 15(12):1326-32. PubMed ID: 12481014
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
[TBL] [Abstract][Full Text] [Related]
13. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity.
van Slooten HJ; van de Vijver MJ; van de Velde CJ; van Dierendonck JH
Br J Cancer; 1998 Mar; 77(5):789-96. PubMed ID: 9514059
[TBL] [Abstract][Full Text] [Related]
14. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R
J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
16. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of p53, Bcl-2, Bax, and Fas proteins in squamous cell carcinomas from immunosuppressed renal transplant recipients and immunocompetent individuals.
Seçkin D; Demirhan B; Karakayali H; Akgün S; Erdal R; Turan M
Transplant Proc; 2002 Sep; 34(6):2139-40. PubMed ID: 12270344
[No Abstract] [Full Text] [Related]
18. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.
Mackey TJ; Borkowski A; Amin P; Jacobs SC; Kyprianou N
Urology; 1998 Dec; 52(6):1085-90. PubMed ID: 9836559
[TBL] [Abstract][Full Text] [Related]
19. [The role of repeated biopsies in prognosis of prostate cancer].
Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis in prostatic adenocarcinomas; a study of relationship to Ki-67 and Bcl-2 protein expression.
Tanji N; Yokoyama M; Sugamoto T; Takeuchi M; Terada N
Anticancer Res; 1998; 18(2A):1111-6. PubMed ID: 9615774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
